AAPL342.92-0.55 (-0.16%) ▼|ABBV284.42-1.00 (-0.35%) ▼|ABT104.32-0.57 (-0.54%) ▼|ACN235.20+5.52 (+2.40%) ▲|ADBE246.56+1.36 (+0.55%) ▲|AMAT417.31+8.02 (+1.96%) ▲|AMD539.43+10.68 (+2.02%) ▲|AMGN428.11-4.39 (-1.01%) ▼|AMT182.00-3.28 (-1.77%) ▼|AMZN262.08+12.08 (+4.83%) ▲|AVGO335.37+6.62 (+2.01%) ▲|AXP315.88+2.29 (+0.73%) ▲|BA191.26+1.05 (+0.55%) ▲|BAC50.45-0.78 (-1.52%) ▼|BKNG161.95-1.50 (-0.92%) ▼|BLK1,125.72-8.66 (-0.76%) ▼|BMY59.10-0.65 (-1.09%) ▼|BNY143.18-0.12 (-0.08%) ▼|BRK-B532.48+0.46 (+0.09%) ▲|C122.37-1.89 (-1.52%) ▼|CAT727.56-3.20 (-0.44%) ▼|CL93.49-0.62 (-0.66%) ▼|CMCSA22.03+0.13 (+0.59%) ▲|COF199.96-1.78 (-0.88%) ▼|COP145.42-1.09 (-0.74%) ▼|COST995.54+6.43 (+0.65%) ▲|CRM242.31+1.61 (+0.67%) ▲|CSCO107.09-0.30 (-0.28%) ▼|CVS91.62-0.74 (-0.80%) ▼|CVX224.99-0.01 (0.00%) ▼|DE629.09-12.77 (-1.99%) ▼|DHR224.75-4.30 (-1.88%) ▼|DIS109.89-0.70 (-0.63%) ▼|DUK119.75-1.72 (-1.42%) ▼|EMR160.78-0.69 (-0.43%) ▼|FDX292.70-0.85 (-0.29%) ▼|GD342.86-1.38 (-0.40%) ▼|GE312.88-0.95 (-0.30%) ▼|GEV911.55-9.65 (-1.05%) ▼|GILD154.70-1.49 (-0.95%) ▼|GM82.61-1.35 (-1.61%) ▼|GOOG340.22+3.31 (+0.98%) ▲|GOOGL344.34+3.75 (+1.10%) ▲|GS875.52-5.74 (-0.65%) ▼|HD310.46+0.83 (+0.27%) ▲|HON210.47-0.95 (-0.45%) ▼|IBM236.90+4.76 (+2.05%) ▲|INTC92.51+2.66 (+2.96%) ▲|INTU325.96+0.81 (+0.25%) ▲|ISRG433.05+6.35 (+1.49%) ▲|JNJ254.24-1.33 (-0.52%) ▼|JPM334.90-4.83 (-1.42%) ▼|KO93.87-0.03 (-0.03%) ▼|LIN504.07+5.64 (+1.13%) ▲|LLY1,251.71-5.32 (-0.42%) ▼|LMT553.09+1.00 (+0.18%) ▲|LOW196.35-1.03 (-0.52%) ▼|LRCX274.09+10.15 (+3.84%) ▲|MA615.72-1.70 (-0.28%) ▼|MCD243.09+0.12 (+0.05%) ▲|MDLZ63.56-0.35 (-0.55%) ▼|MDT93.08-1.67 (-1.76%) ▼|META702.62-6.71 (-0.95%) ▼|MMM163.13-1.63 (-0.99%) ▼|MO74.79-0.32 (-0.43%) ▼|MRK144.48-1.47 (-1.01%) ▼|MS179.14-1.43 (-0.79%) ▼|MSFT534.16+5.11 (+0.97%) ▲|MU905.25+26.41 (+3.00%) ▲|NEE78.35-1.46 (-1.82%) ▼|NFLX69.52-1.01 (-1.43%) ▼|NKE37.11-0.03 (-0.07%) ▼|NOW144.64+2.67 (+1.88%) ▲|NVDA217.40+3.27 (+1.53%) ▲|ORCL130.04+1.81 (+1.41%) ▲|PEP133.22+1.73 (+1.32%) ▲|PFE29.47-0.12 (-0.39%) ▼|PG158.19-1.16 (-0.73%) ▼|PLTR194.27+8.24 (+4.43%) ▲|PM202.88-2.33 (-1.13%) ▼|QCOM173.54+1.43 (+0.83%) ▲|RTX193.17-0.75 (-0.39%) ▼|SBUX98.10+0.58 (+0.59%) ▲|SCHW89.99-1.97 (-2.14%) ▼|SO89.81-1.37 (-1.50%) ▼|SPG202.59-2.85 (-1.39%) ▼|T23.34-0.11 (-0.45%) ▼|TMO679.81-10.19 (-1.48%) ▼|TMUS157.88-1.22 (-0.77%) ▼|TSLA368.00+13.28 (+3.74%) ▲|TXN276.41-0.08 (-0.03%) ▼|UBER70.33-0.03 (-0.04%) ▼|UNH405.18+3.75 (+0.93%) ▲|UNP287.87-1.17 (-0.40%) ▼|UPS97.15-0.33 (-0.34%) ▼|USB58.17-0.57 (-0.96%) ▼|V403.61+1.00 (+0.25%) ▲|VZ44.38-0.41 (-0.92%) ▼|WFC82.48-1.39 (-1.66%) ▼|WMT119.22+0.41 (+0.34%) ▲|XOM178.67-0.31 (-0.17%) ▼|AAPL342.92-0.55 (-0.16%) ▼|ABBV284.42-1.00 (-0.35%) ▼|ABT104.32-0.57 (-0.54%) ▼|ACN235.20+5.52 (+2.40%) ▲|ADBE246.56+1.36 (+0.55%) ▲|AMAT417.31+8.02 (+1.96%) ▲|AMD539.43+10.68 (+2.02%) ▲|AMGN428.11-4.39 (-1.01%) ▼|AMT182.00-3.28 (-1.77%) ▼|AMZN262.08+12.08 (+4.83%) ▲|AVGO335.37+6.62 (+2.01%) ▲|AXP315.88+2.29 (+0.73%) ▲|BA191.26+1.05 (+0.55%) ▲|BAC50.45-0.78 (-1.52%) ▼|BKNG161.95-1.50 (-0.92%) ▼|BLK1,125.72-8.66 (-0.76%) ▼|BMY59.10-0.65 (-1.09%) ▼|BNY143.18-0.12 (-0.08%) ▼|BRK-B532.48+0.46 (+0.09%) ▲|C122.37-1.89 (-1.52%) ▼|CAT727.56-3.20 (-0.44%) ▼|CL93.49-0.62 (-0.66%) ▼|CMCSA22.03+0.13 (+0.59%) ▲|COF199.96-1.78 (-0.88%) ▼|COP145.42-1.09 (-0.74%) ▼|COST995.54+6.43 (+0.65%) ▲|CRM242.31+1.61 (+0.67%) ▲|CSCO107.09-0.30 (-0.28%) ▼|CVS91.62-0.74 (-0.80%) ▼|CVX224.99-0.01 (0.00%) ▼|DE629.09-12.77 (-1.99%) ▼|DHR224.75-4.30 (-1.88%) ▼|DIS109.89-0.70 (-0.63%) ▼|DUK119.75-1.72 (-1.42%) ▼|EMR160.78-0.69 (-0.43%) ▼|FDX292.70-0.85 (-0.29%) ▼|GD342.86-1.38 (-0.40%) ▼|GE312.88-0.95 (-0.30%) ▼|GEV911.55-9.65 (-1.05%) ▼|GILD154.70-1.49 (-0.95%) ▼|GM82.61-1.35 (-1.61%) ▼|GOOG340.22+3.31 (+0.98%) ▲|GOOGL344.34+3.75 (+1.10%) ▲|GS875.52-5.74 (-0.65%) ▼|HD310.46+0.83 (+0.27%) ▲|HON210.47-0.95 (-0.45%) ▼|IBM236.90+4.76 (+2.05%) ▲|INTC92.51+2.66 (+2.96%) ▲|INTU325.96+0.81 (+0.25%) ▲|ISRG433.05+6.35 (+1.49%) ▲|JNJ254.24-1.33 (-0.52%) ▼|JPM334.90-4.83 (-1.42%) ▼|KO93.87-0.03 (-0.03%) ▼|LIN504.07+5.64 (+1.13%) ▲|LLY1,251.71-5.32 (-0.42%) ▼|LMT553.09+1.00 (+0.18%) ▲|LOW196.35-1.03 (-0.52%) ▼|LRCX274.09+10.15 (+3.84%) ▲|MA615.72-1.70 (-0.28%) ▼|MCD243.09+0.12 (+0.05%) ▲|MDLZ63.56-0.35 (-0.55%) ▼|MDT93.08-1.67 (-1.76%) ▼|META702.62-6.71 (-0.95%) ▼|MMM163.13-1.63 (-0.99%) ▼|MO74.79-0.32 (-0.43%) ▼|MRK144.48-1.47 (-1.01%) ▼|MS179.14-1.43 (-0.79%) ▼|MSFT534.16+5.11 (+0.97%) ▲|MU905.25+26.41 (+3.00%) ▲|NEE78.35-1.46 (-1.82%) ▼|NFLX69.52-1.01 (-1.43%) ▼|NKE37.11-0.03 (-0.07%) ▼|NOW144.64+2.67 (+1.88%) ▲|NVDA217.40+3.27 (+1.53%) ▲|ORCL130.04+1.81 (+1.41%) ▲|PEP133.22+1.73 (+1.32%) ▲|PFE29.47-0.12 (-0.39%) ▼|PG158.19-1.16 (-0.73%) ▼|PLTR194.27+8.24 (+4.43%) ▲|PM202.88-2.33 (-1.13%) ▼|QCOM173.54+1.43 (+0.83%) ▲|RTX193.17-0.75 (-0.39%) ▼|SBUX98.10+0.58 (+0.59%) ▲|SCHW89.99-1.97 (-2.14%) ▼|SO89.81-1.37 (-1.50%) ▼|SPG202.59-2.85 (-1.39%) ▼|T23.34-0.11 (-0.45%) ▼|TMO679.81-10.19 (-1.48%) ▼|TMUS157.88-1.22 (-0.77%) ▼|TSLA368.00+13.28 (+3.74%) ▲|TXN276.41-0.08 (-0.03%) ▼|UBER70.33-0.03 (-0.04%) ▼|UNH405.18+3.75 (+0.93%) ▲|UNP287.87-1.17 (-0.40%) ▼|UPS97.15-0.33 (-0.34%) ▼|USB58.17-0.57 (-0.96%) ▼|V403.61+1.00 (+0.25%) ▲|VZ44.38-0.41 (-0.92%) ▼|WFC82.48-1.39 (-1.66%) ▼|WMT119.22+0.41 (+0.34%) ▲|XOM178.67-0.31 (-0.17%) ▼|
18 C
New York
Monday, October 19, 2026

Tag: obesity

newssourceFORcompanycontentinformation1releasesmarket

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are...

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are...

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are...

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /CNW/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are...

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated...

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published...

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

CagriSema Demonstrates Significant Weight Loss in Adults with Obesity

Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with type 2 diabetes CHICAGO, June 22,...

The American Diabetes Association Announces Winners of the Innovation Challenge to Transform Diabetes Care

This challenge Kickstarts additional investments through the new ADA Innovation Fund CHICAGO, June 21, 2025 /PRNewswire/ -- As the American Diabetes Association® (ADA) celebrates its...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy

Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes

Common obesity drug reduced the risk of disease progression by 54% CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular...

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults...

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsObesity

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers